Drawing for OCQUILA

USPTO serial 77673792

OCQUILA

Reviewed by CopyMark Law Group

Reg. 3949710Status 710
Filing date
Status date
Registration date
Apr 26, 2011
Examiner
HUGHITT, ELIZABETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with OCQUILA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Howard N. Aronson

HOWARD N. ARONSON LACKENBACH SIEGEL LLP1 CHASE RDSCARSDALE, NY 10583-4156UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; biochemicals, namely, polypeptides for in vitro research use; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory and scientific research and development use in biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, all of the foregoing for in-vivo useSECTION 8 - CANCELLED—
005Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical purposes in connection with gene therapy, pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, and manufacturing preparations for viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; biochemical and chemical preparations for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposesSECTION 8 - CANCELLED—
010Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposesSECTION 8 - CANCELLED—
042Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products in the field of biotechnology, advisory services relating to the research and development of gene therapy products and clinical trials, conducting clinical trialsSECTION 8 - CANCELLED—
044Medical services; advisory services relating to vaccination regimens; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, in humans and animals, and advisory services relating to the use of pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animalsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 1, 2017C8..CANCELLED SEC. 8 (6-YR)—
Apr 26, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 8, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 8, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 6, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 5, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 5, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 5, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 4, 2011ALIEASSIGNED TO LIE—
Dec 7, 2010ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 7, 2010GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 7, 2010GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 7, 2010CNSISUSPENSION INQUIRY WRITTEN—
Dec 1, 2009GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 1, 2009GNSLLETTER OF SUSPENSION E-MAILED—
Dec 1, 2009CNSLSUSPENSION LETTER WRITTEN—
Nov 20, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 20, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 20, 2009ALIEASSIGNED TO LIE—
Nov 9, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 18, 2009GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 18, 2009GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 18, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 11, 2009DOCKASSIGNED TO EXAMINER—
Feb 23, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 23, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance